A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

The big pharma is paying $66 million upfront for rights to tebipenem in all regions, except Japan and some other Asian countries – where rights are held by Meiji Seika – and will also make a $ ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s ... and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: www.newron.com This document contains ...

The europe viscosupplementation market is on track to witness robust growth over the next decade, with the market projected to rise from USD 523.9 million in 2025 to approximately USD 869.8 million by ...

MILAN, April 01, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients ...

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral ...

MILAN--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases ...

Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...

Apr. 1, 2025 — A team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumors in chicken eggs and analyzing their proteins. The team ...